InflaRx NV (IFRX)
NASDAQ:IFRX
Want to see IFRX full AI Analyst Report?
IFRX Stock Chart & Stats
$1.59
-$0.16(-6.27%)
At close: 4:00 PM EST
$1.59
-$0.16(-6.27%)
Day’s Range― - ―
52-Week Range$0.71 - $2.20
Previous CloseN/A
Volume66.97K
Average Volume (3M)739.26K
Market Cap
$153.98M
Enterprise Value$138.69M
Total Cash (Recent Filing)$46.44M
Total Debt (Recent Filing)$897.53K
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding72,292,860
10 Day Avg. Volume1,547,389
30 Day Avg. Volume739,257
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.39
Price to Sales (P/S)2053.09
P/FCF Ratio-1.70
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue4.92K
Enterprise Value/Gross Profit-18.85
Enterprise Value/Ebitda-2.86
Forecast
1Y Price Target
$8.33Price Target Upside424.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$13.83K
Bulls Say, Bears Say
Bulls Say
Clinical Data And Indication ExpansionPositive topline signals from a Phase 2a basket study in hidradenitis suppurativa and chronic spontaneous urticaria support continued development and point to potential applicability across multiple inflammatory conditions.
Regulatory StrategySecuring FDA agreement on a hidradenitis suppurativa endpoint focused on draining tunnels could allow a more targeted Phase 2b trial design and clarify the path to approval for that indication.
Safety ProfileIzicopan's minimal inhibition of the liver enzyme CYP3A4 reduces the risk of liver toxicity and drug–drug interactions, enabling safer co‑administration with steroid treatments used in inflammatory diseases.
Bears Say
Competitive UncertaintyUnresolved regulatory and data integrity questions surrounding a competing ANCA-associated vasculitis therapy maintain uncertainty in the treatment landscape and could limit immediate market opportunity for new entrants.
Financing RiskA limited cash runway increases the likelihood of needing additional financing, raising the risk of dilutive capital raises and potential execution delays.
Trial And Commercialization RiskFailed or inconclusive clinical trials or poor commercial uptake would undermine valuation and could lead to operational challenges or listing risks.
InflaRx News
IFRX FAQ
What was InflaRx NV’s price range in the past 12 months?
InflaRx NV lowest stock price was $0.71 and its highest was $2.20 in the past 12 months.
What is InflaRx NV’s market cap?
InflaRx NV’s market cap is $153.98M.
When is InflaRx NV’s upcoming earnings report date?
InflaRx NV’s upcoming earnings report date is Jul 30, 2026 which is in 84 days.
How were InflaRx NV’s earnings last quarter?
InflaRx NV released its earnings results on May 06, 2026. The company reported -$0.094 earnings per share for the quarter, beating the consensus estimate of -$0.139 by $0.045.
Is InflaRx NV overvalued?
According to Wall Street analysts InflaRx NV’s price is currently Undervalued.
Does InflaRx NV pay dividends?
InflaRx NV does not currently pay dividends.
What is InflaRx NV’s EPS estimate?
InflaRx NV’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InflaRx NV have?
InflaRx NV has 72,292,860 shares outstanding.
What happened to InflaRx NV’s price movement after its last earnings report?
InflaRx NV reported an EPS of -$0.094 in its last earnings report, beating expectations of -$0.139. Following the earnings report the stock price went up 3.295%.
Which hedge fund is a major shareholder of InflaRx NV?
Currently, no hedge funds are holding shares in IFRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InflaRx Stock Smart Score
Company Description
InflaRx NV
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
IFRX Stock 12 Month Forecast
Average Price Target
$8.33
▲(424.11% Upside)
Technical Analysis
Oramed Pharm
―
Atara Biotherapeutics
―
Anixa Biosciences
―
Clene
―
Acumen Pharmaceuticals
―
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.12% Other Institutional Investors
99.82% Public Companies and
Individual Investors